You are about to leave the Advancing Science, Advancing Care Infosite and view another Ph+ CML resource sponsored by Novartis Pharmaceuticals Corporation.
You are about to leave the Advancing Science, Advancing Care Infosite and view another Ph+ CML resource sponsored by Novartis Pharmaceuticals Corporation.
If you do not wish to leave this site, click Cancel. Or, click OK to continue.
Cancel
OK >
Future goals for Ph+ CML patients are being shaped by an actively evolving paradigm.
Stay up to date with these interactive assets.
Find out more about early
therapies, important milestones,
and the new era of advanced care
Learn more >
Learn how IS RQ-PCR results track progress and inform treatment decisions
A deeper look at why the International Scale is used to standardize results
The mechanism of the disease provides a crucial learning for treating Ph+ CML
Donec convallis arcu id purus gravida volutpat consectetur sit amet nisi. Nulla in massa.
For information about a free trial of IS RQ-PCR, call MolecularMD at 877-459-4979 or
Genoptix at 800-755-1605 and ask about GET RQ-PCR NOW.
To learn more about Ph+ CML treatment options, click here.
AP=accelerated phase. BC=blast crisis. BCR-ABL=breakpoint cluster region-abelson. Ph+ CML=Philadelphia chromosome–positive chronic myeloid leukemia. CBC=complete blood count. CHR=complete hematologic response. mCyR=major cytogenic response. PCyR=partial cytogenetic response. CCyR=complete cytogenetic response. FISH=fluorescence in situ hybridization. ELN=European Leukemia Net. MMR=major molecular response. MR=molecular response. MRD=minimal residual disease. NCCN=National Comprehensive Cancer Network. IS=International Scale. RQ-PCR=real-time quantitative polymerase chain reaction. TKI=tyrosine kinase inhibitor.
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936-1080 © 2012 Novartis 08/12 T-CDE-1047709